New hope for kids with rare gut disease: dupilumab trial launches
NCT ID NCT07257835
First seen Dec 11, 2025 · Last updated May 12, 2026 · Updated 19 times
Summary
This study looks at whether dupilumab can help children with severe eosinophilic gastrointestinal disorders (EGIDs) that haven't responded to other treatments. About 20 children will receive the drug to see if it heals ulcers and lowers inflammation in the gut. The goal is to control the disease and improve symptoms, not to cure it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EOSINOPHILIC GASTROINTESTINAL DISORDERS (EGIDS) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
201102
RECRUITINGShanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.